Precision Medicine in Oncology®

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

The NCCN has issued a category 2A recommendation for revumenib in relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

Taletrectinib was approved in Japan for advanced non–small cell lung cancer harboring ROS1 fusions.

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

TT125-802 has received FDA fast track designations in EGFR+ and KRAS G12C+ advanced NSCLC.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.